Post by ClearView Healthcare Partners

We’re back with another episode of ClearView Convos! In this episode we again look at pricing and access, as Mike Rizzo and Rishi Dalsania break down the recent FTC settlement with Express Scripts (ESI) and what it means for PBMs, biopharma pricing, and access strategy.   The conversation unpacks how the FTC’s move to decouple PBM revenue from spread pricing could reshape rebate transparency and rewrite compensation models. Mike and Rishi discuss how the settlement may alter how biopharma companies negotiate with PBMs, and they explore how PBMs could adapt financially through alternative structures. They also touch on the onshoring of ESI’s GPO Ascent, a potential lever for PBMs to maintain market control and offset revenue shifts.   Tune in for our perspective on an important policy moment and what it signals for the evolving U.S. drug pricing ecosystem. Watch the full episode here 👉 https://lnkd.in/eZX4NWJn #ClearViewConvos #DrugPricing #MarketAccess #PBMs #BiopharmaStrategy #ClearViewConvos #ClearViewHCP #FTC #ESI

Video Content